Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
212
datasets available to search
ShareScore release 0.9.0
Dataset results
212 results for “thyroid carcinoma”
Supplemental Material from: Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like
<p>Supplemental Material from: Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like</p>
STRA6 promotes thyroid carcinoma progression via activation of the ILK/AKT/mTOR axis in cells and female nude mice
<p><span><strong>Background</strong>: </span><span>Metastasis has emerged to be an important cause for poor prognosis of thyroid carcinoma (TC) and its molecular mechanisms are not fully understood. STRA6 is a multifunctional membrane protein widely expressed in embryonic and adult tissues. The function and mechanism of STRA6 in TC remain elusive.</span></p> <p><strong><span>Objective</span></strong><span>: We aimed to explore the role of STRA6 in TC progression and provide a therapeutic target for TC.</span></p> <p><span><strong>Methods</strong>: </span><span>The expression and clinicopathological relevance of STRA6 were explored in TC. Stable STRA6-knockdown TC cells were established and used to determine the biological function of STRA6 <em>in</em> <em>vitro</em> and <em>in</em> <em>vivo</em>. RNA-sequencing and Co-immunoprecipitation were performed to unveil the molecular mechanism of STRA6 in TC progression. The potential of STRA6 as a therapeutic target was evaluated by lipid nanoparticles (LNPs) containing siRNA.</span></p> <p><span><strong>Results</strong>:</span><span> STRA6 was upregulated in TC and correlated with aggressive clinicopathological features including extrathyroidal extension and lymph node metastasis, which contributed to the poor prognosis of TC. STRA6 facilitated TC progression by enhancing proliferation and metastasis <em>in</em> <em>vitro</em> and <em>in</em> <em>vivo</em>. Mechanistically, STRA6 could interact with ILK and subsequently activate the AKT/mTOR signaling pathway. We further unveiled that STRA6 reprogrammed lipid metabolism through SREBP1, which was crucial for the metastasis of TC. Moreover, STRA6 siRNA delivered by LNP significantly inhibited cell growth in xenograft tumor models.</span></p> <p><span><strong>Conclusions</strong>:</span><span> Our study demonstrates the critical roles of STRA6 contributing to TC progression via the ILK/AKT/mTOR axis, which may provide a novel prognostic marker as well as a promising therapeutic target for aggressive TC.</span></p>
Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
ClinicalTrials.gov study NCT03753919. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
ClinicalTrials.gov study NCT01534897. IPD Sharing: NO. Countries: 1. Publications: 1.
Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound
ClinicalTrials.gov study NCT07357571. IPD Sharing: YES. Countries: 1. Publications: 11.
STRA6 promotes thyroid carcinoma progression via activation of the ILK/AKT/mTOR axis in cells and female nude mice
Open the record for dataset details and reuse information.
Supplemental Material from: Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes with Different Treatment Needs
<p>Supplemental data from: <strong>Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes with Different Treatment Needs</strong></p>
Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes with Different Treatment Needs: Supplemental Material
<p>Supplemental Material from: Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes with Different Treatment Needs</p>
Supplemental Material from: Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes with Different Treatment Needs
<p>Supplemental Data from "Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes with Different Treatment Needs"</p>
Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.
ClinicalTrials.gov study NCT06067594. IPD Sharing: YES. Countries: 1. Publications: 8.
The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma
ClinicalTrials.gov study NCT06268600. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
ClinicalTrials.gov study NCT00435851. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Retro-Auricular Single-Site Endoscopic to Papillary Thyroid Carcinoma
ClinicalTrials.gov study NCT05263141. IPD Sharing: NO. Countries: 1. Publications: 11.
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
ClinicalTrials.gov study NCT04522570. IPD Sharing: YES. Countries: 1. Publications: 9.
Proteomics of Papillary Thyroid Carcinoma
ClinicalTrials.gov study NCT02814032. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma
ClinicalTrials.gov study NCT04683575. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma
ClinicalTrials.gov study NCT00887107. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
ClinicalTrials.gov study NCT05007093. IPD Sharing: NO. Countries: 1. Publications: 1.
Multicenter Study Differentiated Thyroid Carcinoma
ClinicalTrials.gov study NCT00144079. IPD Sharing: Not stated. Countries: 3. Publications: 8.
Deep Learning-Based Intraoperative Dual-tracer Video Analysis of Sentinel Lymph Node Mapping for Metastasis Prediction in cN0 Papillary Thyroid Carcinoma
ClinicalTrials.gov study NCT07391514. IPD Sharing: UNDECIDED. Countries: 1. Publications: 46.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.